share_log

Esperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare Conference

Esperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare Conference

Esperion將參加即將舉行的派傑投資第36屆年度醫療大會
GlobeNewswire ·  11/21 13:00

ANN ARBOR, Mich., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 2024 Piper Sandler 36th Annual Healthcare Conference on Thursday, December 5, 2024, at 12:30 p.m. ET.

ANN ARBOR, Mich., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 2024 Piper Sandler 36th Annual Healthcare Conference on Thursday, December 5, 2024, at 12:30 p.m. Et.

The live webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company's website for approximately 90 days.

可以通過Esperion網站的投資者和媒體欄目訪問直播。直播重播將在通話結束後約兩個小時提供,並將存檔於公司網站上約90天。

Esperion Therapeutics
At Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases. The status quo is not meeting the health needs of millions of people with high cholesterol – that is why our team of passionate industry leaders is breaking through the barriers that prevent patients from reaching their goals. Providers are moving toward reducing LDL-cholesterol levels as low as possible, as soon as possible; we provide the next steps to help get patients there. Because when it comes to high cholesterol, getting to goal is not optional. It is our life's work. For more information, visit esperion.com and esperionscience.com and follow us on X at twitter.com/EsperionInc.

esperion therapeutics
At Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases. The status quo is not meeting the health needs of millions of people with high cholesterol – that is why our team of passionate industry leaders is breaking through the barriers that prevent patients from reaching their goals. Providers are moving toward reducing LDL-cholesterol levels as low as possible, as soon as possible; we provide the next steps to help get patients there. Because when it comes to high cholesterol, getting to goal is not optional. It is our life's work. For more information, visit esperion.com and esperionscience.com and follow us on X at twitter.com/EsperionInc.

Esperion Contact Information:
Investors:
Alina Venezia
investorrelations@esperion.com
(734) 887-3903

Esperion聯繫信息:
投資者:
Alina Venezia
investorrelations@esperion.com
(734) 887-3903

Media:
Tiffany Aldrich
corporateteam@esperion.com
(616) 443-8438

媒體:
Tiffany Aldrich
corporateteam@esperion.com
(616) 443-8438


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論